Ventus Therapeutics, a clinical-stage biopharmaceutical company with two novel small-molecule programs entering Phase 2 ...

Privately-held Ventus Therapeutics, a biopharma with two novel small-molecule programs entering Phase II development for ...

We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ: CYTK) stands ...

MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical company with two novel small-molecule programs ... a division of Eli Lilly's Catalyze360, where she served ...

New York, New York-- (Newsfile Corp. - February 23, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and ...

The leading Extensive-Stage Small Cell Lung Cancer Companies such as Shanghai Henlius Biotech, MacroGenics, Inc., RayzeBio, ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Perceive Pharma, a pharmaceutical company pioneering novel small molecule therapeutics in ophthalmology, today announced the closing of a $15M Series A funding round including Deerfield Management, ...

In truth, BioAge was forced to discontinue the STRIDES Phase 2 trial after several subjects exhibited elevated liver enzyme levels, indicating potential organ damage. Consequently, the Company ...